BioDuro Initiates Effort to Develop COVID-19 Nanobody Therapeutic

SAN DIEGO–(BUSINESS WIRE)–BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has initiated a COVID-19 nanobody therapeutic program, leveraging the company’s biologics discovery platform and a specialized COVID-19 dedicated team. The cornerstone of the effort includes screening more than 10 billion human synthetic antibodies generated using Artificial Intelligence (AI) computing and high-speed DNA mutagenesis technology. BioDuro’

Click to view original post